# Bausch & Lomb Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Bausch & Lomb Corp).

## Overview

Bausch & Lomb Corp is an eye-health company built around products used to correct, protect, and treat vision across the full patient lifecycle. Its portfolio spans contact lenses, lens care, intraocular lenses, surgical systems, and prescription and consumer eye-care products, giving it exposure to both consumer and clinical channels. The company operates as a fully integrated business with research, manufacturing, and commercial capabilities in roughly 100 countries. It was founded in 1853 and became a separately traded public company in 2022 after being carved out from Bausch Health Companies.

## Products & services

• Contact lenses and daily disposable lens brands
• Lens care and cleaning solutions
• Intraocular lenses (IOLs) and surgical implants
• Ophthalmic surgical systems and devices
• Prescription eye medications and pharmaceuticals
• Consumer eye health products, vitamins, and supplements

- **Vision Care** (57%) — Contact lenses, lens care, and consumer eye-health products sold through retail and eye-care channels.
- **Pharmaceuticals** (25%) — Prescription and branded/generic ophthalmic medicines used to treat eye conditions.
- **Surgical** (18%) — Intraocular lenses, surgical equipment, and related products used in ophthalmic procedures.

- Contact lenses, including SiHy Daily lenses and Bausch + Lomb Ultra
- Lens care products for cleaning, disinfecting, and storing lenses
- Intraocular lenses (IOLs) used in cataract and other eye surgery
- Ophthalmic surgical systems and related devices
- Prescription eye medications and branded/generic pharmaceuticals
- Consumer eye-care products such as Lumify and PreserVision
- Vitamin and mineral supplements for eye health

## Customers

Bausch & Lomb sells to a mix of professional, institutional, and retail customers rather than to a single end market. Eye-care professionals, ophthalmic surgeons, hospitals, and ambulatory surgery centers buy its surgical and prescription products because they are used in clinical treatment and procedures. Wholesalers, large retailers, pharmacies, and independent eye-care practices buy the company’s vision-care and consumer products for resale or recommendation to patients. End consumers are also important, especially for contact lenses, lens care, dry-eye products, and supplements that are purchased directly or through retail channels. The company’s broad portfolio supports cross-selling across these customer groups and helps it participate in both recurring consumable demand and procedure-driven demand.

- **Eye-care professionals** (primary) — Optometrists and ophthalmologists buy or recommend contact lenses, lens care, and consumer eye-health products because they influence patient selection and recurring usage.
- **Hospitals and ambulatory surgery centers** (primary) — These institutions buy IOLs and surgical systems for cataract and other ophthalmic procedures, where product performance and reliability are critical.
- **Wholesalers and distributors** (primary) — They purchase prescription and OTC eye-health products for downstream resale and are important for broad market access.
- **Retailers and pharmacies** (secondary) — Large and mid-sized retailers, pharmacies, and mass merchants buy consumer eye-care brands to serve over-the-counter demand.
- **End consumers** (secondary) — Consumers buy contact lenses, dry-eye products, vitamins, and supplements for everyday vision correction and eye-health maintenance.

- Eye-care professionals who recommend and fit contact lenses and lens care products
- Ophthalmic surgeons and physicians who use IOLs and surgical systems
- Hospitals and ambulatory surgery centers that buy surgical devices and implants
- Wholesalers and distributors that stock prescription and OTC eye-health products
- Large retailers and pharmacies that sell consumer eye-care and supplement brands
- Consumers who purchase contact lenses, dry-eye products, and supplements

## Geography

Bausch & Lomb has a global operating footprint with commercial presence in approximately 100 countries, so its revenue base is geographically diversified rather than concentrated in one market. The United States remains a major market, supported by a large commercial team and direct relationships with wholesalers, retailers, and eye-care practices. The company also relies on international commercial teams and distribution partners across Europe, Asia, Latin America, the Middle East, and Africa, which broadens reach but increases foreign-exchange and regulatory exposure. Because products are sold across many countries and channels, local reimbursement, pricing, and supply-chain conditions can affect performance differently by region. The company’s manufacturing and commercial network is global, which helps serve local demand but also creates exposure to cross-border logistics and compliance risks.

- **United States** (0%) — No country-level revenue split was disclosed in the provided excerpts.
- **International** (0%) — The excerpts disclose global presence but not a revenue split by country or region.

- Commercial presence in approximately 100 countries
- United States is a core market with a dedicated commercial team
- International sales are supported by local commercial teams and distribution partners
- Europe, Asia, Latin America, the Middle East, and Africa are important markets
- Global manufacturing and R&D footprint supports local supply and product launches
- Foreign exchange movements affect reported revenue and margins
- Regional reimbursement and pricing conditions can vary materially

## Strategy

The company’s strategy centers on being a full-spectrum eye-health platform rather than a single-product business, which allows it to sell across vision care, pharmaceuticals, and surgical care. Management is emphasizing cross-selling across product lines and customer channels, using its broad portfolio to deepen relationships with eye-care professionals, retailers, and surgical sites. The company is also focused on product innovation and portfolio performance, as shown by growth in dry-eye products, Lumify, PreserVision, and key contact lens brands. On the capital structure side, Bausch & Lomb is working through post-separation refinancing and longer-term debt positioning, which matters because leverage can constrain flexibility for acquisitions and product investment. It also continues to consider licensing and acquisition opportunities to expand the portfolio and support growth.

- **Grow core consumer and contact lens brands** (short-term) — These products drive recurring demand and help the company maintain shelf space and patient loyalty in a competitive market.
- **Strengthen cross-segment commercial execution** (medium-term) — Selling multiple eye-health categories through the same customer relationships improves reach and supports cross-selling.
- **Refinance and optimize capital structure** (short-term) — Lower financing risk and a longer-dated debt profile improve flexibility for investment and acquisitions.
- **Pursue selective acquisitions and licensing** (medium-term) — Portfolio expansion can fill product gaps and add growth in adjacent eye-health categories.

- Use a broad eye-health portfolio to cross-sell across vision, pharma, and surgical channels
- Defend and grow core brands such as Lumify, PreserVision, and Bausch + Lomb Ultra
- Expand commercial reach through wholesalers, retailers, pharmacies, and eye-care practices
- Invest in product development and acquisitions to refresh the portfolio
- Refinance and extend the debt structure after separation from Bausch Health
- Improve operating execution through business transformation and cost initiatives

## Risks

Bausch & Lomb faces a highly competitive eye-health market where product quality, efficacy, pricing, and promotion determine share, so new products from rivals can quickly pressure sales. Its business depends on manufacturing continuity and third-party supply chains, making it vulnerable to plant disruptions, single-source components, inventory swings, and distributor buying patterns. The company also has meaningful international exposure, so foreign exchange volatility, geopolitical disruption, and local regulatory changes can affect revenue and costs. Separation-related execution risk remains important because the company is still managing debt refinancing and the long-term implications of operating independently from Bausch Health. In addition, reimbursement pressure, product recalls, and litigation or indemnity obligations can affect both demand and profitability in a business that sells regulated medical and consumer eye-care products.

- **Manufacturing and supply-chain interruptions** [high] — The company relies on its own plants and third-party manufacturers, so outages or compliance failures can stop shipments and create shortages.
- **Competitive pressure and product substitution** [high] — The market includes large pharma, device, OTC, and generic competitors, which can erode pricing and share if rivals launch better or cheaper products.
- **Foreign exchange and international operations risk** [medium] — A large share of business is outside the U.S., so currency moves and regional instability can affect reported revenue and margins.
- **Debt and refinancing risk** [high] — Higher leverage can raise interest expense, limit strategic flexibility, and make the company more sensitive to credit-market conditions.
- **Product recall and regulatory risk** [high] — Medical devices and pharmaceuticals are subject to quality, safety, and regulatory oversight, and recalls can create charges and reputational damage.

- Intense competition across contact lenses, pharmaceuticals, OTC, and surgical products
- Manufacturing or third-party supply disruptions can interrupt product availability
- Single-source or limited-source components increase operational fragility
- Distributor inventory swings and wholesaler concentration can distort demand
- Foreign exchange and geopolitical risk affect international revenue and costs
- Separation and refinancing execution could increase leverage or financing costs
- Product recalls, reimbursement pressure, and regulatory compliance can hurt sales

## Accounting

Revenue is primarily recognized on product sales, so reported results are sensitive to shipment timing, channel inventory, returns, allowances, and chargebacks, especially in retail and wholesaler channels. The company also has some alliance, licensing, and contract manufacturing revenue, which can create different timing and margin patterns than direct product sales. Quarterly results can fluctuate because volumes, pricing, foreign exchange, acquisitions, and product discontinuations affect each segment differently, and surgical results can be hit by recall-related charges such as inventory obsolescence. Management also highlights contingent consideration, restructuring and integration costs, litigation settlements, and debt-related cash requirements, all of which can create judgment-heavy accruals and nonrecurring items. Investors should also watch goodwill and intangible asset impairment risk in a business built around brands, acquired products, and regulatory approvals.

- **Revenue recognition and deductions** — Affects reported revenue and gross margin
- **Inventory obsolescence and recall charges** — Affects cost of sales and segment profit
- **Contingent consideration and litigation accruals** — Affects SG&A, other expenses, and cash requirements
- **Goodwill and intangible asset impairment** — Can materially affect operating income and equity
- **Debt and refinancing accounting** — Affects finance costs, leverage ratios, and cash flow

- Product revenue timing depends on shipment, returns, chargebacks, and allowances
- Alliance, licensing, and contract manufacturing revenue can have different recognition patterns
- Quarterly results can swing with volume, pricing, FX, acquisitions, and discontinuations
- Recall-related inventory obsolescence and other charges can affect surgical margins
- Contingent consideration and litigation accruals require management judgment
- Goodwill and intangible assets are important because the business is brand- and acquisition-heavy
- Debt refinancing and interest costs affect reported earnings and cash flow

---

*Last updated: 2026-08-11T04:46:23.475936+00:00*